deltatrials
Recruiting OBSERVATIONAL NCT02688894

The Molecular Screening Study for the Umbrella Trial (SUKSES) in Relapsed Small Cell Lung Cancer Patients [SUKSES-S]

Sponsor: Samsung Medical Center

Conditions Neuroendocrine Carcinoma Small Cell Lung Cancers
Interventions No treatment is included in this protocol.
Updated 16 times since 2017 Last updated: Apr 23, 2026 Started: Apr 29, 2016 Primary completion: Sep 1, 2028 Completion: Dec 1, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Neuroendocrine Carcinoma and Small Cell Lung Cancers and is currently actively recruiting participants. Samsung Medical Center leads this study, which shows 16 recorded versions since 2016 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Study Description(click to expand)

This protocol is a molecular screening protocol only. No drug intervention study will be included in this protocol. Based on the molecular profiling, patients may be eligible for drug intervention study of SUKSES trial. This procedure (molecular profiling) can be performed before, during, or after the initial treatment. DNA will be extracted from the archived or fresh tissue and blood. NGS-based cancer panel and Nanostring CNV will be tested with DNA from tissue and/or blood. Immunohistochemistry and FISH will be done by pathologists using archived or fresh tissue. In addition, blood collection will be conducted at Baseline (initial), three weeks, six weeks, twelve weeks, and subsequent imaging. Tumor tissues (fresh or archival) will be analyzed using NGS-based cancer panel, nanostring CNV, immunohistochemistry and/or FISH. Specific methods of each molecular tests will be defined with standard laboratory manual developed by pathologists.

This protocol is a molecular screening protocol only. No drug intervention study will be included in this protocol. Based on the molecular profiling, patients may be eligible for drug intervention study of SUKSES trial.

This procedure (molecular profiling) can be performed before, during, or after the initial treatment.

DNA will be extracted from the archived or fresh tissue and blood. NGS-based cancer panel and Nanostring CNV will be tested with DNA from tissue and/or blood.

Immunohistochemistry and FISH will be done by pathologists using archived or fresh tissue.

In addition, blood collection will be conducted at Baseline (initial), three weeks, six weeks, twelve weeks, and subsequent imaging.

Tumor tissues (fresh or archival) will be analyzed using NGS-based cancer panel, nanostring CNV, immunohistochemistry and/or FISH. Specific methods of each molecular tests will be defined with standard laboratory manual developed by pathologists.

Status Flow

~Jan 2017 – ~Mar 2018 · 14 months · monthly snapshot~Mar 2018 – ~Apr 2018 · 31 days · monthly snapshot~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshot~Jun 2018 – ~Sep 2019 · 15 months · monthly snapshot~Sep 2019 – ~May 2020 · 8 months · monthly snapshot~May 2020 – ~Jan 2021 · 8 months · monthly snapshot~Jan 2021 – ~Oct 2021 · 9 months · monthly snapshot~Oct 2021 – ~Dec 2022 · 14 months · monthly snapshot~Dec 2022 – ~Feb 2023 · 2 months · monthly snapshot~Feb 2023 – ~Feb 2024 · 12 months · monthly snapshot~Feb 2024 – ~Jul 2024 · 5 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – ~Jan 2026 · 4 months · monthly snapshot~Jan 2026 – ~May 2026 · 4 months · monthly snapshotMay 4, 2026 – present · 2 months · daily API

Change History

16 versions recorded

  1. May 4, 2026 — Present [daily]

    Recruiting

    Status: Unknown → Recruiting

  2. Jan 2026 — May 2026 [monthly]

    Unknown

    Status: Recruiting → Unknown

  3. Sep 2025 — Jan 2026 [monthly]

    Recruiting

  4. Sep 2024 — Sep 2025 [monthly]

    Recruiting

  5. Jul 2024 — Sep 2024 [monthly]

    Recruiting

▶ Show 11 earlier versions

  1. Feb 2024 — Jul 2024 [monthly]

    Recruiting

  2. Feb 2023 — Feb 2024 [monthly]

    Recruiting

  3. Dec 2022 — Feb 2023 [monthly]

    Recruiting

  4. Oct 2021 — Dec 2022 [monthly]

    Recruiting

  5. Jan 2021 — Oct 2021 [monthly]

    Recruiting

  6. May 2020 — Jan 2021 [monthly]

    Recruiting

  7. Sep 2019 — May 2020 [monthly]

    Recruiting

  8. Jun 2018 — Sep 2019 [monthly]

    Recruiting

  9. Apr 2018 — Jun 2018 [monthly]

    Recruiting

    Phase: NA → None

  10. Mar 2018 — Apr 2018 [monthly]

    Recruiting NA

    Status: Not Yet Recruiting → Recruiting

  11. Jan 2017 — Mar 2018 [monthly]

    Not Yet Recruiting NA

    First recorded

Apr 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

This protocol is a molecular screening protocol only. No drug intervention study will be included in this protocol. Based on the molecular profiling, patients may be eligible for drug intervention study of SUKSES trial. This procedure can be performed during or after the first-line treatment. DNA will be extracted from the archived or fresh tissue and blood. NGS-based cancer panel and Nanostring CNV will be tested with DNA from tissue and/or blood. Immunohistochemistry and FISH will be done by pathologists using archived or fresh tissue. Tumor tissues (fresh or archival) will be analyzed using NGS-based cancer panel, nanostring CNV, immunohistochemistry and/or FISH. Specific methods of each molecular tests will be defined with standard laboratory manual developed by pathologists.

Contact Information

Sponsor contact:
  • Samsung Medical Center
Data source: ClinicalTrials.gov

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations